Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Open Access
- 1 March 2002
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 25 (3) , 542-549
- https://doi.org/10.2337/diacare.25.3.542
Abstract
OBJECTIVE—Traditional cardiovascular risk factors (CVRF) only partly explain the excessive risk of cardiovascular disease in patients with type 2 diabetes. There is now an increasing appreciation for many novel CVRF that occur largely as a result of insulin resistance and hyperinsulinemia. Therefore, we investigated whether diabetes medications that vary in their mechanism of action and ability to reduce insulin resistance may differ in their effects on both traditional and novel CVRF.Keywords
This publication has 52 references indexed in Scilit:
- Antihyperglycemic Treatment in Diabetics with Coronary Disease: Increased Metformin-Associated Mortality over a 5-Year Follow-UpCardiology, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Increase of lipoprotein (a) with troglitazoneThe Lancet, 1997
- Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II DiabetesArchives of internal medicine (1960), 1997
- The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II DiabetesDiabetes Care, 1996
- Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.Journal of Clinical Investigation, 1995
- Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groupsDiabetes Care, 1993
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986